2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Robert Dreicer, MD, discusses the impact of the phase 3 CHAARTED trial in metastatic castration-sensitive prostate cancer.
Robert Dreicer, MD, director, solid tumor oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center, discusses the impact of the phase 3 CHAARTED trial (NCT00309985) in metastatic castration-sensitive prostate cancer (mCSPC).
The intensification of androgen deprivation therapy (ADT) became the standard of care for patients with mCSPC following CHAARTED and subsequent clinical trials that explored combinations with ADT backbones, Dreicer says. Though the uptake of this data has not been as successful as previously hoped, intensification presents the ability to improve survival of patients between 1 or 2 years on average, which is an unprecedented increase in solid tumor oncology, Dreicer explains.
Now that intensification has morphed into the standard of care for patients with mCSPC, it is vital to ensure that all patients in this treatment space receive ADT-based combinations when appropriate, Dreicer concludes.